|
시장보고서
상품코드
2107851
티카그렐러 시장 : 제형별, 적응증별, 유통 채널별, 지역별Ticagrelor Market, By Strength, By Indication, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
티카그렐러 시장 규모는 2026년에 21억 달러로 추정되고 있으며, 2033년까지 33억 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 7.4%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 21억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.40% | 2033년 시장 규모 예측 : | 33억 달러 |
혈소판 응집 억제제로 일반적으로 사용되는 티카그렐로는 2011년 7월 미국 식품의약국(USFDA)으로부터 2010년 12월에는 유럽 집행위원회로부터 유럽연합(EU)내 승인을 획득했습니다. 티카그렐러는 급성 관상동맥 증후군 또는 ST 상승형 심근경색 환자에서 뇌졸중이나 심근경색 등의 혈전성 사건 예방에 사용됩니다.
시장 역학
심혈관 질환 유병률의 증가는 고령 인구 증가와 생활 방식의 변화에 기인합니다. 세계보건기구(WHO)에 따르면 매년 약 1,790만 명이 심혈관 질환(CVD)으로 사망하고 있으며, 이는 전 세계 사망자 수의 약 31%를 차지합니다. 이러한 상황은 향후 10년 동안 티카그렐로의 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.
또한 2016년 9월 WHO는 ‘세계 심장 구상(Global Hearts Initiative)’를 출범시켜 전 세계 각국 정부가 심혈관 질환의 예방 및 관리를 위한 노력을 강화할 수 있도록 지원하고 있습니다. 따라서 심혈관 질환 예방을 지원하기 위한 정부 및 비정부 기구의 노력 증가는 예측 기간 중 치카그렐롤 시장의 성장을 촉진할 것으로 예상됩니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 규명하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공합니다.
- 본 조사에서는 다음 매개변수를 바탕으로 전 세계 티카그렐러 시장의 주요 기업 개요을 소개합니다. : 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 정부 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 티카그렐러 시장 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체를 비롯해 조사·컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 티카그렐러 시장 : 강도별, 2021-2033년
제5장 세계의 티카그렐러 시장 : 적응증별, 2021-2033년
제6장 세계의 티카그렐러 시장 : 유통 채널별, 2021-2033년
제7장 세계의 티카그렐러 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.08.12Ticagrelor Market is estimated to be valued at USD 2.1 Bn in 2026 and is expected to reach USD 3.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.1 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.40% | 2033 Value Projection: | USD 3.3 Bn |
Ticagrelor, a drug commonly used as a platelet aggregation inhibitor, received approval from U.S. Food and Drug Administration (USFDA) in July 2011 and in the European Union by the European Commission in December, 2010. Ticagrelor is used for the prevention of thrombotic events such as stroke or heart attack in people with acute coronary syndrome or myocardial infarction with ST wave elevation.
Market Dynamics
Rising prevalence of cardiovascular diseases is attributed to rising geriatric population and changing lifestyles. According to World Health Organization (WHO), around 17.9 million people every year die due to cardiovascular diseases (CVDs), which is about 31% of all global deaths. This is expected to positively impact growth of the ticagrelor market over the next decade.
Furthermore, in September 2016, WHO launched the Global Hearts Initiative through which WHO is supporting governments around the world to improve efforts on CVD prevention and control. Thus, increasing number of non-government and government initiatives, in order to aid in prevention of CVD is expected to help in propelling growth of the ticagrelor market over the forecast period.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global ticagrelor market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, ANHUI HAIKANG PHARMACEUTICAL CO., LTD., Avra Laboratories Pvt Ltd., and Sun Pharmaceutical Industries Ltd
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global ticagrelor market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for ticagrelor market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- By Strength (Revenue, USD Bn, 2021-2033)
- 60 mg
- 90 mg
- By Indication (Revenue, USD Bn, 2021-2033)
- Acute Coronary Syndrome
- Ischemic Stroke
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- C.H. Boehringer Sohn AG & Ko. KG
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Natco Pharma Limited
- Anhui Haikang Pharmaceutical Co., Ltd.
- Avra Laboratories Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Strength
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Historical Overview
- Merger and Acquisition
- Regulatory Scenario
- PORTER'S Five Forces
- PEST Analysis
4. Global Ticagrelor Market, By Strength, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- 60 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 90 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Ticagrelor Market, By Indication, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Acute Coronary Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Ticagrelor Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Ticagrelor Market, By Regions, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022-2033
- Regional Trends
- North America
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Strength, 2021-2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- C.H. Boehringer Sohn AG & Ko. KG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Natco Pharma Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- ANHUI HAIKANG PHARMACEUTICAL CO., LTD.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Avra Laboratories Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- C.H. Boehringer Sohn AG & Ko. KG
9. Section
- References
- Research Methodology
- About us and Sales Contact
